Medlatest’s Weekly “View From The Med” Online Now

Back on the quest for regulatory nirvana, this week’s editorial looks at two events which arguably characterise the state of play. In the U.S. Abbott’s MitraClip gets the thumbs down from the FDA, but sees the expert panel give it the thumbs up, which is interesting.

And in Europe, industry body Eucomed launches its “don’t lose the 3” campaign, in what is a very direct challenge to regulators not to go to far and end up with the worst of all worlds… no guarantee of better or safer products and a big fact guarantee of delays to market.

You can read it here.